Biotechnology

Techseriesinsight > Blog > News > Biotechnology

Cyrex Launches BiomeBurden™ for Immune Sensitivity Testing

June 20, 2025
PRNewswire
Biotechnology, News

Anixa Biosciences to Host an Investor Webcast on June 26, 2025

Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host an investor webcast presentation on June...

June 19, 2025
PRNewswire
Biotechnology, News

Saol Therapeutics Announces Poster Presentation at the UMDF Mitochondrial Medicine 2025 Conference

Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced the presentation of key findings from the Phase III trial of Sodium Dichloroacetate (DCA) for Pyruvate Dehydrogenase Complex Deficiency...

June 19, 2025
tsi_admin
Biotechnology, News

Aspen Laser and TheraLight Announce Key Executive Appointments to Support Growth and Innovation

Aspen Laser Systems, LLC and TheraLight, LLC, pioneers in photobiomodulation and integrative wellness technologies, are pleased to announce the appointment of two key executives, effective June 6, 2025. These strategic...

June 18, 2025
PRNewswire
Biotechnology, News

KLOTHO NEUROSCIENCES (KLTO) ANNOUNCES MUTUAL TERMINATION OF SHARE EXCHANGE AGREEMENT WITH SKYBELL TECHNOLOGIES (SKYBELL), TO CONTINUE ITS FOCUS ON THERAPEUTICS AND LONGEVITY PROGRAMS

Key highlights of the announcement include: Today announced that on June 13, 2025, it entered into a Termination and Release Agreement with SkyBell Technologies, Inc. (“SkyBell”), formally ending the Share...

June 17, 2025
PRNewswire
Biotechnology

Ratio Therapeutics and Nusano Enter Long-Term, Multi-Isotope Supply Agreement to Boost Production of Cancer Radiopharmaceuticals

Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, and Nusano, a physics company enabling breakthrough radioisotope supplies, today...

June 16, 2025
PRNewswire
Biotechnology

BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced new survival data from 10 participants in its Expanded Access Program...

June 16, 2025
PRNewswire
Biotechnology

Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation

Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company redefining treatment paradigms through inflammation-targeted and resilience-driven therapies, today announced the successful completion of its first-in-human Phase 1 clinical trial evaluating HT-4253...

June 13, 2025
PRNewswire
Biotechnology

Green Fertilizer Made with Air and Plasma: NitroCapt (Sweden) wins $2M Food Planet Prize 2025 for developing low-emission fertilizers

The Curt Bergfors Foundation is honored to announce that NitroCapt was awarded the Food Planet Prize, the world’s biggest environmental award, on June 13 in Stockholm, Sweden. This recognition highlights their exceptional contributions and potential to...

June 13, 2025
PRNewswire
Biotechnology

Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine

On June 12, Keymed Biosciences Inc. (HKEX: 02162) announced that Prof. Jun Shi’s research team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology,...

June 13, 2025
PRNewswire
Biotechnology

Ratio Therapeutics Partners with Macrocyclics for Exclusive Manufacturing and Distribution of its Radiopharmaceutical Chelator Platform

Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, announced today that it entered into an agreement granting Macrocyclics Inc....